Alliancebernstein L.P. Monte Rosa Therapeutics, Inc. Transaction History

Alliancebernstein L.P.

$261 Billion
Q1 2025

A detailed history of Alliancebernstein L.P. transactions in Monte Rosa Therapeutics, Inc. stock. As of the latest transaction made, Alliancebernstein L.P. holds 35,140 shares of GLUE stock, worth $139,505. This represents 0.0% of its overall portfolio holdings.

Number of Shares

35,140

Previous 35,140 -0.0%

Holding current value

$139,505

Previous $243,000 32.92%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$3.59 - $6.97 $8,472 - $16,449	2,360 Added 7.2%	35,140 $186,000
Q2 2024 Aug 14, 2024	BUY	$3.38 - $7.86 $31,129 - $72,390	9,210 Added 39.08%	32,780 $122,000
Q3 2023 Nov 14, 2023	BUY	$4.78 - $7.22 $8,221 - $12,418	1,720 Added 7.87%	23,570 $112,000
Q2 2023 Aug 15, 2023	BUY	$4.53 - $8.4 $34,654 - $64,260	7,650 Added 53.87%	21,850 $149,000
Q1 2023 May 15, 2023	BUY	$5.95 - $8.21 $10,710 - $14,778	1,800 Added 14.52%	14,200 $110,000
Q4 2022 Feb 14, 2023	BUY	$6.71 - $9.72 $83,204 - $120,528	12,400 New	12,400 $94,000
Q2 2022 Aug 15, 2022	SELL	$6.15 - $14.99 $500,007 - $1.22 Million	-81,302 Closed	0 $0
Q1 2022 May 13, 2022	SELL	$10.36 - $20.41 $91,862 - $180,975	-8,867 Reduced 9.83%	81,302 $1.14 Million
Q4 2021 Feb 14, 2022	BUY	$16.28 - $27.15 $93,154 - $155,352	5,722 Added 6.78%	90,169 $1.84 Million
Q3 2021 Nov 10, 2021	SELL	$18.59 - $42.21 $1.02 Million - $2.31 Million	-54,648 Reduced 39.29%	84,447 $1.88 Million
Q2 2021 Jul 30, 2021	BUY	$18.86 - $22.7 $2.62 Million - $3.16 Million	139,095 New	139,095 $3.16 Million

Others Institutions Holding GLUE

# of Institutions

108

Shares Held

53.4M

Call Options Held

69.1K

Put Options Held

22.4K

View Full List

About Monte Rosa Therapeutics, Inc.

Ticker GLUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,713,900
Market Cap $185M
Description
Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing prot...

More about GLUE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Alliancebernstein L.P., based on Form 13F filings with the SEC.

News

Stay updated on Alliancebernstein L.P. with notifications on news.

Account

Alliancebernstein L.P. Monte Rosa Therapeutics, Inc. Transaction History